- Home
- SANA vs TBPH Comparison
SANA vs TBPH Comparison
Compare SANA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- TBPH
- Stock Information
- Founded
- SANA 2018
- TBPH 2013
- Country
- SANA United States
- TBPH United States
- Employees
- SANA N/A
- TBPH N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- SANA Health Care
- TBPH Health Care
- Exchange
- SANA Nasdaq
- TBPH Nasdaq
- Market Cap
- SANA 519.8M
- TBPH 464.5M
- IPO Year
- SANA 2021
- TBPH N/A
- Fundamental
- Price
- SANA $1.71
- TBPH $9.45
- Analyst Decision
- SANA Strong Buy
- TBPH Buy
- Analyst Count
- SANA 5
- TBPH 3
- Target Price
- SANA $9.50
- TBPH $11.33
- AVG Volume (30 Days)
- SANA 4.1M
- TBPH 223.0K
- Earning Date
- SANA 05-07-2025
- TBPH 05-12-2025
- Dividend Yield
- SANA N/A
- TBPH N/A
- EPS Growth
- SANA N/A
- TBPH N/A
- EPS
- SANA N/A
- TBPH N/A
- Revenue
- SANA N/A
- TBPH $64,381,000.00
- Revenue This Year
- SANA N/A
- TBPH $51.09
- Revenue Next Year
- SANA N/A
- TBPH N/A
- P/E Ratio
- SANA N/A
- TBPH N/A
- Revenue Growth
- SANA N/A
- TBPH 12.12
- 52 Week Low
- SANA $1.26
- TBPH $7.44
- 52 Week High
- SANA $10.50
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- SANA 45.52
- TBPH 62.39
- Support Level
- SANA $1.53
- TBPH $8.44
- Resistance Level
- SANA $1.92
- TBPH $8.82
- Average True Range (ATR)
- SANA 0.20
- TBPH 0.45
- MACD
- SANA 0.05
- TBPH 0.11
- Stochastic Oscillator
- SANA 68.18
- TBPH 96.27
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).